329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab

by Richard Brown, John Beadle, Tom Lillie, Andrew Stone, Sarah Lockwood, Andrew Fox, Eirini Bournazou
Published 2020-11-01

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

by Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R. Duffy, Simon Alvis, Brian Champion, André Lieber, Terry Hermiston, Len W. Seymour, John Beadle, Kerry Fisher
Published 2017-06-01

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

by Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle, Emiliano Calvo
Published 2019-01-01

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

by Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo, Kerry Fisher
Published 2017-09-01

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

by Arthur Dyer, Ying Di, Hugo Calderon, Sam Illingworth, Gray Kueberuwa, Alison Tedcastle, Phil Jakeman, Suet Lin Chia, Alice Brown, Michael A. Silva, David Barlow, John Beadle, Terry Hermiston, David J.P. Ferguson, Brian Champion, Kerry D. Fisher, Leonard W. Seymour
Published 2017-03-01